Immuneering Dirección

Dirección controles de criterios 3/4

El CEO de Immuneering es Ben Zeskind , nombrado en Feb 2008, tiene una permanencia de 16.75 años. compensación anual total es $1.92M, compuesta por 30.9% salario y 69.1% primas, incluidas acciones y opciones de la empresa. posee directamente un 10.71% de las acciones de la empresa, por valor de $6.67M. La antigüedad media del equipo directivo y de la junta directiva es de 3.2 años y 3.8 años, respectivamente.

Información clave

Ben Zeskind

Chief Executive Officer (CEO)

US$1.9m

Compensación total

Porcentaje del salario del CEO	30.9%
Permanencia del CEO	16.8yrs
Participación del CEO	10.7%
Permanencia media de la dirección	3.2yrs
Promedio de permanencia en la Junta Directiva	3.8yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Ben Zeskind en comparación con los beneficios de Immuneering?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-US$58m
Jun 30 2024	n/a	n/a	-US$56m
Mar 31 2024	n/a	n/a	-US$54m
Dec 31 2023	US$2m	US$593k	-US$53m
Sep 30 2023	n/a	n/a	-US$52m
Jun 30 2023	n/a	n/a	-US$52m
Mar 31 2023	n/a	n/a	-US$51m
Dec 31 2022	US$2m	US$570k	-US$51m
Sep 30 2022	n/a	n/a	-US$48m
Jun 30 2022	n/a	n/a	-US$44m
Mar 31 2022	n/a	n/a	-US$40m
Dec 31 2021	US$2m	US$400k	-US$34m
Sep 30 2021	n/a	n/a	-US$29m
Jun 30 2021	n/a	n/a	-US$24m
Mar 31 2021	n/a	n/a	-US$20m
Dec 31 2020	US$806k	US$293k	-US$17m

Compensación vs. Mercado: La compensación total de Ben($USD1.92M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD647.72K).

Compensación vs. Ingresos: La compensación de Ben ha sido consistente con los resultados de la empresa en el último año.

CEO

Ben Zeskind (41 yo)

16.8yrs

Permanencia

US$1,918,201

Compensación

Dr. Benjamin J. Zeskind, also known as Ben, Ph D., MBA serves as the Co-Founder, President, Chief Executive Officer and Director of Immuneering Corporation since February 2008 and served as its Secretary....

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Benjamin Zeskind	Co-Founder	16.8yrs	US$1.92m	10.71% $ 6.7m
Robert Carpenter	Co-Founder & Chair Emeritus	16.8yrs	US$202.74k	3.87% $ 2.4m
Brett Hall	Chief Scientific Officer	5yrs	US$1.40m	1.17% $ 726.4k
Harold Brakewood	Chief Business Officer	1.7yrs	US$1.57m	0.013% $ 8.2k
Mallory Morales	Principal Financial & Accounting Officer	2.3yrs	sin datos	0.043% $ 26.7k
Paula George	Director of Accounting & Operations and Assistant Corporate Controller	3.2yrs	sin datos	sin datos
Michael Bookman	Chief Legal Officer & Secretary	3.3yrs	sin datos	0.013% $ 8.1k
Leah Neufeld	Chief People Officer	2.1yrs	sin datos	0.034% $ 21.1k
Peter King	Head of Discovery & VP	no data	sin datos	sin datos
Praveen Nair	Head of Translational Pharmacology & VP	2.7yrs	sin datos	sin datos
Stephen Sebastian	Executive Director & Corporate Controller	3.2yrs	sin datos	sin datos

3.2yrs

Permanencia media

51yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de IMRX se considera experimentado (3.2 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Benjamin Zeskind	Co-Founder	16.8yrs	US$1.92m	10.71% $ 6.7m
Robert Carpenter	Co-Founder & Chair Emeritus	15.5yrs	US$202.74k	3.87% $ 2.4m
Laurie Keating	Independent Director	3.7yrs	US$179.88k	0.047% $ 29.4k
Douglas Lauffenburger	Co-Chairman of Scientific Advisory Board	no data	sin datos	sin datos
Peter Feinberg	Director	3.8yrs	US$165.67k	3.7% $ 2.3m
Ann Berman	Independent Chair	3.3yrs	US$181.38k	0.23% $ 141.7k
Diana Hausman	Independent Director	2.8yrs	US$175.38k	0% $ 0
Max Artyomov	Co-Chairman of Scientific Advisory Board	no data	sin datos	sin datos
Bijan Nejadnik	Member of Scientific Advisory Board	no data	sin datos	sin datos
Tanios Bekaii-Saab	Member of Scientific Advisory Board	no data	sin datos	sin datos
Daniel Ahn	Member of Scientific Advisory Board	no data	sin datos	sin datos
Denis Guttridge	Member of Scientific Advisory Board	no data	sin datos	sin datos

3.8yrs

Permanencia media

63yo

Promedio de edad

Junta con experiencia: La junta directiva de IMRX se considera experimentada (3.8 años de antigüedad promedio).

Immuneering Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Immuneering Corporation, Annual General Meeting, Jun 12, 2024

Independent Chair recently bought US$123k worth of stock

Less than half of directors are independent

Immuneering Corporation Appoints Thomas J. Schall to Its Board of Directors

Immuneering Corporation Appoints Mallory Morales as Chief Accounting Officer, Effective July 1, 2023

Immuneering Corporation Appoints Leah R. Neufeld as Chief People Officer

Recent updates

Immuneering Corporation Announces Positive Initial Phase 2A Data Including Complete and Partial Responses with Imm-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients

Companies Like Immuneering (NASDAQ:IMRX) Could Be Quite Risky

Immuneering Corporation(NasdaqGM:IMRX) dropped from Russell Small Cap Comp Value Index

Is Immuneering (NASDAQ:IMRX) In A Good Position To Deliver On Growth Plans?

Immuneering Corporation, Annual General Meeting, Jun 12, 2024

Immuneering Corporation Presents Preclinical Data At the American Association for Cancer Research Annual Meeting

Immuneering Announces First Patient Dosed in Its Phase 1/2A Trial of Imm-6-415 to Treat Advanced Solid Tumors with Raf or Ras Mutations

Independent Chair recently bought US$123k worth of stock

Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone

Price target decreased by 12% to US$16.86

Immuneering Announces Positive Topline Results from Phase 1 Portion of Its Phase 1/2A Clinical Trial of IMM-1-104 in Ras-Mutant Solid Tumors

New major risk - Share price stability

Less than half of directors are independent

Immuneering Corporation Appoints Thomas J. Schall to Its Board of Directors

Immuneering Doses First Patient in Phase 2A Clinical Trial of IMM-1-104 in Ras-Mutant Solid Tumors

New major risk - Revenue and earnings growth

Immuneering Corporation Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer

Is Immuneering (NASDAQ:IMRX) In A Good Position To Deliver On Growth Plans?

New major risk - Share price stability

Third quarter 2023 earnings released: US$0.43 loss per share (vs US$0.49 loss in 3Q 2022)

New minor risk - Share price stability

Immuneering Corporation Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference

We're Not Very Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Rate

First half 2023 earnings released: US$0.93 loss per share (vs US$0.93 loss in 1H 2022)

Immuneering Corporation Appoints Mallory Morales as Chief Accounting Officer, Effective July 1, 2023

New major risk - Revenue and earnings growth

First quarter 2023 earnings released: US$0.51 loss per share (vs US$0.49 loss in 1Q 2022)

Price target decreased by 12% to US$18.71

Consensus revenue estimates decrease by 80%, EPS upgraded

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$21.33

Immuneering Corporation Announces First Patient Dosed in its Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations

Consensus revenue estimates fall by 26%

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Immuneering Corporation Appoints Leah R. Neufeld as Chief People Officer

Immuneering To Present Poster on IMM-6-415 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations

Immuneering wins FDA nod to study lead asset in solid tumors

Immuneering Corporation Announces Committee Changes

Consensus forecasts updated

Immuneering Announces Submission of IND Application to the FDA for Phase 1/2A Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations

Immuneering seeks FDA nod to conduct clinical trial for lead cancer candidate

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Immuneering Corporation Announces Management Changes

Immuneering initiated a Buy by Chardan, PT set to $18

Immuneering Corporation(NasdaqGM:IMRX) dropped from Russell 2500 Value Index

Immuneering Reports Data in Two Preclinical Abstracts at the ASCO 2022 Annual Meeting Highlighting Pan-KRAS/NRAS Activity of IMM-1-104

Consensus forecasts updated

First quarter 2022 earnings: EPS misses analyst expectations

Immuneering Corporation, Annual General Meeting, Jun 21, 2022

Consensus revenue estimates fall by 75%

Full year 2021 earnings: EPS and revenues miss analyst expectations

Immuneering Corporation Reports Preclinical Data on IMM-1-104 in NRAS Mutant Melanoma Model

Immuneering Corporation (NasdaqGM:IMRX) acquired BioArkive, Inc. from Brett Hall, Praveen Nair, Daniel Flynn, Thomas Barr, Anna Travesa and Dennis Garland for $8.5 million.

Third quarter 2021 earnings released: US$0.47 loss per share

Director recently bought US$116k worth of stock

Director recently bought US$131k worth of stock

Less than half of directors are independent

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad